Prescribing information and Adverse event reporting can be found at the bottom of the page

Brand Navigation Banner

Search Header

Bayer in women's health

For almost a century, Bayer has been working to make a positive difference to women’s health through pioneering research and innovation.


In the 1920s, Bayer—then called Schering AG—made a significant contribution to understanding the molecular structure of sex hormones and launched the world's first oestrogen preparation for menopause management. This firmly set Bayer as a pioneer in women’s healthcare and, in 1961, Bayer became the first company to launch a contraceptive pill in Europe, the combined oral contraceptive Anovlar® (norethisterone acetate/ethinylestradiol)1. Anovlar is no longer produced.


More recent innovations include the introduction of Kyleena® (19.5mg intrauterine delivery system levonorgestrel) a low-dose, levonorgestrel-releasing intrauterine delivery system which was launched in the UK in 2018.2

Bayer’s innovations in women’s health timeline:


First European birth control pill, the combined oral contraceptive Anovlar® (norethisterone/ethinylestradiol). Anovlar is no longer produced.

Progestogen-only pill (mini-pill)

First levonorgestrel-releasing IUS, Mirena® (52mg intrauterine delivery system levonorgestrel), launched in the UK in 19951

Progestogen-only emergency contraception, launched in the UK

Low-estrogen dose contraceptive pill

First pill to treat premenstrual dysphoric disorder, a severe form of premenstrual syndrome, in the US for women who choose the contraceptive pill for birth control

Jaydess® (13.5mg intrauterine delivery system levonorgestrel) was launched in 2014

First oral contraceptive pill to contain the oestrogen estradiol valerate, an oestrogen that is immediately converted to estradiol in a woman’s body, Qlaira® (estradiol valerate/dienogest)2

First birth control pill approved for the treatment of heavy menstrual bleeding, Qlaira®

Kyleena® (19.5mg intrauterine delivery system levonorgestrel), a low-dose levonorgestrel-releasing IUS was launched in the UK in 2018

Present day

  • Costescu DJ. Levonorgestrel-releasing intrauterine systems for long-acting contraception: current perspectives, safety, and patient counseling. Int J Womens Health. 2016;8:589–598. Published 2016 Oct 13. doi:10.2147/IJWH.S99705 Return to content
  • Bayer Plc. Qlaira®, film-coated tablets: Summary of Product Characteristics [online]. Updated 17 December 2018. Available from: [Last accessed: January 2022]. Return to content

Bayer offers a number of contraception methods for women, depending on their personal needs. These include:

PP-PF-WHC-GB-1006 May 2022

Search Footer

Reporting adverse events and quality complaints


Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Bayer plc.


If you want to report an adverse event or quality complaint, reports can be directed to: Tel: 011820‍63500 or email:


Further information is available on the “contact” tab at